China Pharma Holdings, Inc. (CPHI) stock
CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
$0.54−0.01 (-1.43%)
Close on Nov 11, 2026Market cap $23.37MP/E –Yield –
China Pharma gross margin
Gross margin is gross profit as a percentage of revenue.
China Pharma's gross margin for the twelve months ending Jun 30, 2026 was 11.8%. For fiscal 2025 it was -3.2%, against -43.8% the year before. The highest annual figure on record is 40.7% in fiscal 2010.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3.2% | +40.7 |
| FY2024 | Dec 31, 2024 | -43.8% | −39.8 |
| FY2023 | Dec 31, 2023 | -4.0% | +2.1 |
| FY2022 | Dec 31, 2022 | -6.1% | −9.7 |
| FY2021 | Dec 31, 2021 | 3.6% | −14.3 |
| FY2020 | Dec 31, 2020 | 18.0% | +4.4 |
| FY2019 | Dec 31, 2019 | 13.6% | −2.4 |
| FY2018 | Dec 31, 2018 | 16.0% | −2.7 |
| FY2017 | Dec 31, 2017 | 18.7% | −2.0 |
| FY2016 | Dec 31, 2016 | 20.7% | +13.5 |
| FY2015 | Dec 31, 2015 | 7.2% | −4.9 |
| FY2014 | Dec 31, 2014 | 12.1% | +13.5 |
| FY2013 | Dec 31, 2013 | -1.5% | −27.3 |
| FY2012 | Dec 31, 2012 | 25.8% | −9.9 |
| FY2011 | Dec 31, 2011 | 35.7% | −5.0 |
| FY2010 | Dec 31, 2010 | 40.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 8.8% | +17.3 |
| Q1 FY2026 | Mar 31, 2026 | 29.0% | +41.0 |
| Q4 FY2025 | Dec 31, 2025 | 12.3% | +26.5 |
| Q3 FY2025 | Sep 30, 2025 | -7.9% | +39.3 |
| Q2 FY2025 | Jun 30, 2025 | -8.5% | +101.3 |
| Q1 FY2025 | Mar 31, 2025 | -12.0% | +9.2 |
| Q4 FY2024 | Dec 31, 2024 | -14.2% | −10.5 |
| Q3 FY2024 | Sep 30, 2024 | -47.2% | −34.3 |
| Q2 FY2024 | Jun 30, 2024 | -109.8% | −96.4 |
| Q1 FY2024 | Mar 31, 2024 | -21.2% | −30.2 |
| Q4 FY2023 | Dec 31, 2023 | -3.7% | −5.1 |
| Q3 FY2023 | Sep 30, 2023 | -12.9% | −5.9 |
| Q2 FY2023 | Jun 30, 2023 | -13.4% | +0.9 |
| Q1 FY2023 | Mar 31, 2023 | 9.1% | +19.6 |
| Q4 FY2022 | Dec 31, 2022 | 1.5% | −9.0 |
| Q3 FY2022 | Sep 30, 2022 | -7.0% | +8.0 |
| Q2 FY2022 | Jun 30, 2022 | -14.2% | −17.2 |
| Q1 FY2022 | Mar 31, 2022 | -10.6% | −22.1 |
| Q4 FY2021 | Dec 31, 2021 | 10.4% | −8.7 |
| Q3 FY2021 | Sep 30, 2021 | -15.0% | −16.9 |
| Q2 FY2021 | Jun 30, 2021 | 2.9% | −27.6 |
| Q1 FY2021 | Mar 31, 2021 | 11.6% | +0.5 |
| Q4 FY2020 | Dec 31, 2020 | 19.2% | +9.7 |
| Q3 FY2020 | Sep 30, 2020 | 2.0% | −13.7 |
| Q2 FY2020 | Jun 30, 2020 | 30.5% | +24.1 |
| Q1 FY2020 | Mar 31, 2020 | 11.0% | −11.4 |
| Q4 FY2019 | Dec 31, 2019 | 9.5% | +14.8 |
| Q3 FY2019 | Sep 30, 2019 | 15.7% | −6.6 |
| Q2 FY2019 | Jun 30, 2019 | 6.4% | −11.9 |
| Q1 FY2019 | Mar 31, 2019 | 22.4% | −6.7 |
| Q4 FY2018 | Dec 31, 2018 | -5.3% | −23.0 |
| Q3 FY2018 | Sep 30, 2018 | 22.3% | +9.0 |
| Q2 FY2018 | Jun 30, 2018 | 18.3% | −4.0 |
| Q1 FY2018 | Mar 31, 2018 | 29.1% | +7.3 |
| Q4 FY2017 | Dec 31, 2017 | 17.7% | −15.5 |
| Q3 FY2017 | Sep 30, 2017 | 13.3% | +2.1 |
| Q2 FY2017 | Jun 30, 2017 | 22.2% | – |
| Q1 FY2017 | Mar 31, 2017 | 21.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 33.2% | – |
| Q3 FY2016 | Sep 30, 2016 | 11.2% | – |
See a number that looks wrong?